Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-05-24 DOI:10.1038/s41541-025-01145-6

Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku

引用次数: 0

Abstract

This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.

查看原文本刊更多论文

比较Moderna的mRNA-1083和辉瑞的流感和COVID-19双靶点mRNA疫苗。

本文综述了Moderna的mRNA-1083和辉瑞/BioNTech的mRNA-1020/1030新冠肺炎和流感双靶标疫苗。两者都利用mRNA技术，显示出强大的免疫原性和良好的安全性。Moderna的mRNA-1083表现出了更好的免疫应答，而辉瑞的mRNA-1020/1030表现良好，但对乙型流感的效果略差。这些疫苗简化了免疫策略，增强了保护作用，并强调了全球疫苗公平的必要性，以防止未来的疫情。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.